Amgen Inc.’s disclosed that US regulators paused the study of an early-stage obesity drug, a lucrative market the company is trying to crack.

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

Pfizer’s PFE 2024 revenue reached $63.6 billion, near the high end of its $61 billion-$64 billion guidance range. Management ...

Robert F Kennedy Jr has promised to Make America Healthy Again. Is his plan woo-woo or common sense? - RFK Jr’s plans to shake up American healthcare read like a wacky wellness guru meets green ...

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...

Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting treatment effectiveness.

Just over a year after striking an obesity deal with Novo Nordisk, an SEC filing shows Flagship Pioneering spinout Omega Therapeutics is days away from bankruptcy and will lay off up to 17 employees.

The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market ...

Tech entrepreneur Bryan Johnson, who was recently in India, walked out of a podcast recording with Zerodha co-founder Nikhil ...

Johnson, 47, recently visited India to record a podcast with Kamath for his show "WTF" in a five star hotel, but despite ...

The AP-NORC survey shows about half of U.S. adults believe it is a good thing for adults to use Ozempic, Wegovy and similar ...

The American CEO, who focuses on age-reversing products, shared that during the podcast recording, the Air Quality Index (AQI ...